Fortis Healthcare Q1FY25: Revenue jumps 12.2%, PAT 40.4%

Fortis Healthcare has announced Q1FY25 results.

Consolidated revenue jumped 12.2% YoY to Rs 1,859 crore in Q1FY25 as against Rs 1,657 crore in Q1FY24.

PAT jumped 40.4 percent to Rs 174 crore in Q1FY25 as against Rs 124 crore in Q1FY24.

Operating EBITDA jumped 25.5 percent YoY in Q1FY25 to Rs 343 crore as against Rs 273 crore in Q1FY24.

“The mainstay of our performance continues to be the hospital business which presently contributes approx. 84% to our consolidated EBITDA. We are progressing well on our plans to add a capacity of close to 700 beds in this fiscal year across our key facilities including Faridabad, Anandpur, Shalimar Bagh, and Noida, and will also be shortly commissioning the 350-bed Manesar facility which we acquired in FY24. In addition, given the Company’s strong Balance Sheet, we continue to evaluate inorganic growth opportunities in our key focus clusters. The diagnostics business performance is lower than the corresponding previous quarter, largely due to the impact of brand change but has witnessed signs of early improvement versus the trailing quarter. The new brand is being well accepted and gaining prominence; placing the business in a better position to further scale up its performance,” said Ravi Rajagopal, Chairman, Board of Directors, Fortis Healthcare.

“We have witnessed a good start to the fiscal as reflected in our Q1 earnings. The hospital business continues to show an upward momentum with Operating EBITDA margins expanding 330 bps at 18.5% versus Q1 FY24, a growth of 39%. This was primarily led by an increase in occupancy from 64% in Q1 FY24 to 67% in Q1 FY25 and a higher ARPOB. Most of our key facilities have performed well noticeably Mulund, Anandpur, BG Road, and Shalimar Bagh. Amongst our focus specialties Neuro Sciences and Oncology have grown a robust 23% and 22% respectively versus the corresponding previous period. We have strengthened our clinical talent in the medical specialties of Cardiac Sciences, Neurology, and Orthopaedics in the quarter and have also commissioned South Asia’s first Gamma Knife Espirit radiosurgery equipment for neurosurgical treatment at FMRI. On the diagnostics business while revenues remain muted, Operating EBITDA margins are better than the trailing quarter showing signs of a gradual recovery which we expect to continue through FY25,” said Dr Ashutosh Raghuvanshi, MD and CEO, Fortis Healthcare.
MB Bureau